The pharmaceutical industry is bracing for one of the most significant patent cliff events in its history as Eliquis, the blockbuster anticoagulant developed by Bristol Myers Squibb (BMS) and Pfizer, approaches the expiration of its market exclusivity. Projected to result in approximately $14 billion in revenue losses over a six-year period, the impending loss of exclusivity (LOE) for Eliquis serves as a stark illustration of how swiftly generic competition can erode the market dominance of even the most entrenched pharmaceutical brands. This event is poised to reshape the financial landscape for both BMS and Pfizer, necessitating strategic shifts in capital allocation and future growth planning.
Eliquis, known chemically as apixaban, has been a cornerstone of cardiovascular therapy since its initial approval. Its journey began in the European Union in May 2011, followed by U.S. Food and Drug Administration (FDA) approval in December 2012. As a direct factor Xa inhibitor, it has become a leading treatment for a range of conditions, including stroke prevention in patients with non-valvular atrial fibrillation, and the treatment and prevention of venous thromboembolic events such as deep vein thrombosis and pulmonary embolism. Its widespread clinical adoption and broad prescriber base have solidified its position as the dominant oral anticoagulant globally, contributing significantly to the coffers of its developers.
The scale of the projected revenue loss is staggering. Global sales of Eliquis reached an impressive $14.4 billion in 2025, positioning it among the highest-grossing small-molecule drugs in the industry. However, forecasts indicate a dramatic decline, with sales anticipated to plummet to just $205 million by 2031. This represents a near-total erosion of 98.6% of its market value, marking it as one of the most substantial single-asset LOE events in recent pharmaceutical history. The decline is not a uniform drop but rather a geographically sequenced event, with European exclusivity lapsing first, followed by the larger markets of the United States and Japan.
A Geographically Sequenced Revenue Erosion
The impact of Eliquis’s patent expiration will unfold in distinct phases across key global markets. The initial wave of revenue compression is expected to be concentrated in markets outside the United States. Rest of World (ROW) revenues are projected to experience a significant decline of nearly 75% between 2025 and 2027. This sharp decrease will be largely driven by the entry of generic versions into European markets, where established tendering systems and formulary-level switching mechanisms can rapidly displace branded drug volumes once exclusivity lapses.
In contrast, the U.S. market is anticipated to remain relatively insulated during this initial period. Consequently, the U.S. market’s share of Eliquis’s total portfolio revenue is expected to rise to nearly 90% by 2027, as the drug becomes increasingly concentrated in its last high-value geographic stronghold. This strategic geographic sequencing highlights the differing regulatory and market dynamics that influence the pace of generic adoption.
The U.S. Market: A Steep Decline Post-Exclusivity
The most significant revenue erosion for Eliquis is anticipated in the United States, where patent exclusivity is set to expire later. However, even before the formal patent cliff, U.S. revenues are already facing pressure. Under the provisions of the Inflation Reduction Act (IRA), a maximum fair price of $231 per 30-day supply for Medicare beneficiaries took effect in January 2026. This negotiation mechanism has begun to reduce net revenues for Eliquis two years ahead of its patent expiration, signaling an early impact of policy changes on the drug’s commercial trajectory.
When U.S. exclusivity officially lapses in 2028, the impact is projected to be immediate and severe. A single-year decline of nearly 50% is anticipated, driven by the rapid dynamics of generic substitution prevalent in the U.S. market. Factors such as formulary switches and automatic substitution at the point of dispensing can lead to swift volume shifts within quarters of a generic drug’s launch. By 2031, U.S. revenues for Eliquis are forecast to have fallen by a staggering 99% from their 2025 peak, accounting for over $10 billion of the total projected losses during the six-year forecast period.
Timeline of Exclusivity Loss and Market Impact
- May 2026: European patent exclusivity for Eliquis expires. This marks the commencement of significant revenue decline in Europe and other ex-U.S. markets.
- January 2026: The Inflation Reduction Act’s Medicare Maximum Fair Price negotiation for Eliquis takes effect, beginning to impact U.S. net revenues prior to patent expiry.
- 2027: U.S. market share of total Eliquis revenue increases significantly as ex-U.S. markets experience substantial declines.
- 2028: U.S. patent exclusivity for Eliquis expires. This event triggers a rapid and substantial drop in U.S. sales due to swift generic substitution.
- 2031: Eliquis sales are projected to be below $1 billion globally, with the vast majority of losses incurred between 2026 and 2031.
Strategic Repositioning in Response to the Cliff
The impending LOE for Eliquis has compelled Bristol Myers Squibb to undertake a significant strategic repositioning of its business. The market has long anticipated this patent cliff, and the company has been actively preparing for this eventuality. A key element of this strategy involves substantial investments in mergers and acquisitions (M&A) to cultivate new growth platforms that can offset the anticipated revenue decline.
BMS has made multibillion-dollar acquisitions, notably Karuna Therapeutics for $1 billion and RayzeBio for $4.1 billion. These acquisitions represent deliberate strategic bets on the future potential of neuroscience and radiopharmaceuticals as significant revenue drivers. The Karuna acquisition has already yielded a tangible result: Cobenfy (formerly KarXT) received FDA approval in September 2024 for the treatment of schizophrenia. This marks the first new class of schizophrenia treatment in over five decades and commercially launched in the U.S. in late 2024. The early success of Cobenfy signals that BMS’s M&A-led repositioning strategy is beginning to demonstrate efficacy, providing a potential revenue stream ahead of the most severe phase of Eliquis’s sales erosion.
Broader Implications for the Pharmaceutical Industry
The Eliquis LOE event is of paramount importance as it will serve as a critical benchmark for assessing the speed and magnitude of revenue decline for major cardiovascular brands transitioning to generic status. The projected drop in Eliquis sales from approximately $14.4 billion in 2025 to well below $1 billion within roughly five years underscores a central theme in the contemporary pharmaceutical landscape: the substantial risk associated with heavy reliance on a single, blockbuster asset.
For large-cap pharmaceutical companies, an over-dependence on a single product can expose them to rapid and profound value erosion once patent protection lapses. This reality emphasizes that early and proactive diversification of the product portfolio is not merely an option but an essential strategic imperative for long-term financial health and sustained growth in an increasingly competitive and dynamic market. The lessons learned from the Eliquis patent cliff will undoubtedly influence strategic planning and investment decisions across the industry for years to come, reinforcing the critical need for robust pipelines and diversified revenue streams.
While official statements from Bristol Myers Squibb and Pfizer have acknowledged the anticipated LOE event and highlighted their strategies for managing the transition, the precise financial impact and the effectiveness of their diversification efforts will be closely scrutinized by investors and industry analysts. The robust nature of Eliquis’s market penetration prior to LOE means that the speed of its decline will be a significant indicator of how quickly established market leaders can be disrupted by generic competition in the modern era. The industry’s ability to navigate such substantial patent cliffs will be a defining characteristic of its resilience and adaptability in the coming decade.
Leave a Reply